TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01700075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weight loss treatment
Description: Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
Study: NCT01154296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESPECT-2 Counseling
Description: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.
Study: NCT01545778

Intervention type: DRUG
Intervention: Tapentadol IR
Description: Opioid naive patients exposed to tapentadol IR from July 2009 to December 2010.
Study: NCT03970148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nd: YAG laser
Description: Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
Study: NCT01171703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: femoral-popliteal bypass
Description: Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
Study: NCT02874651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Patients will take oral apatinib. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
Study: NCT01545778

Intervention type: DRUG
Intervention: Oxycodone IR
Description: Opioid naive patients exposed to Oxycodone IR from July 2009 to December 2010.
Study: NCT00915460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Avonex)
Description: dosage and frequency as per Biogen Idec protocol
Study: NCT02874651

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take oral placebo. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
Study: NCT01534884

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 1000 mg by intravenous (IV) infusion. Each patient may receive 2 courses of treatment.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 1000 mg by intravenous (IV) infusion. Each patient may receive 2 courses of treatment.
Study: NCT01257659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STARR rectocele repair
Description: The STARR transanal stapling system is used to repair a rectocele.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elevate mesh rectocele repair
Description: A posterior Elevate mesh is placed transvaginally to repair a rectocele.
Study: NCT04803578

Intervention type: OTHER
Intervention: Conventional physiotherapy
Description: The subjects will receive rehabilitation according to the guidelines on the management of subjects after knee or hip arthroplasty, recovery of joint Range of Motion, recovery of lower limb strength, education to the crutches management, and stairs climbing and descending

Intervention type: OTHER
Intervention: Conventional physiotherapy
Description: The subjects will receive rehabilitation according to the guidelines on the management of subjects after knee or hip arthroplasty, recovery of joint Range of Motion, recovery of lower limb strength, education to the crutches management, and stairs climbing and descending
Study: NCT01979731

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Job rotation
Description: The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guidelines ergonomics
Description: Orientation about manual material handling, posture, furniture, rest break and others in general.
Study: NCT03032354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12
Description: Combination therapy of probiotics during 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, (Placebo group)
Description: Placebo during 6 months
Study: NCT03763955

Intervention type: BEHAVIORAL
Intervention: MIRT
Description: 4 week MIRT provide:~1. front to front treatment (1 hour/day for 5 days/week)~2. treatment with robotic devices (1 hour/day for 5 days/week)~3. occupational therapy (1 hour/day for 5 days/week)
Study: NCT03626441

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger.
Study: NCT02403843

Intervention type: DEVICE
Intervention: RNS System
Description: The RNS System provides closed loop responsive brain stimulation. In response to detection of previously identified electrocorticographic activity, the neurostimulator delivers stimulation to the seizure foci by way of the leads to interrupt the activity before the patient experiences clinical seizures. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
Study: NCT00601003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox
Description: 30mg/kg/day PO divided into TID dosing q day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m2/dose in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 0.75mg/m2/dose, in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
Study: NCT02708433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine
Study: NCT01654081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
Study: NCT03729024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Adjustable lens (LAL) and Light Delivery Device (LDD)
Description: Primary and Fellow eyes will receive Light adjustable lens with Light delivery Device treatments
Study: NCT03203694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking: Intervention arm in diabetics
Description: The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking: No intervention in diabetics
Description: Subjects will be instructed to continue their usual lifestyle for 8 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Walking: Healthy cohort as reference controls
Description: Subjects will be studied at one time only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower body heating: Intervention arm in healthy subjects
Description: This intervention consists of 60 minutes of lower body heating (40-42 degree C).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower body heating: Intervention arm in diabetics
Description: This intervention consists of 60 minutes of lower body heating (40-42 degree C) 7 days per week for 7 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Lower body heating: Healthy cohort as reference controls
Description: Subjects will be studied at one time only.
Study: NCT02430363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK - 3475
Description: Administered Intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Suppressor of the PI3K/Akt pathways
Description: Capsules orally with food
Study: NCT01720784

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alginate dietary fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alginate dietary fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02122653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight training
Description: Participants will perform 4 weeks of Weight training for lower extremities.
Study: NCT01171703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
Study: NCT01717482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Standard of Care Observation
Study: NCT01675570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10045
Description: One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle for RX-10045
Description: One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
Study: NCT00782184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40
Description: ezetimibe/simvastatin 10/40 tablet once daily for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin 40 mg
Description: atorvastatin 40 mg tablet once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin 20 mg
Description: All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin 20 mg
Description: All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization
Study: NCT01072435

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled sedation
Description: Administration of short-acting anesthetic propofol via self-administration device.Single bolus-dose 1ml(10mg)of propofol,lockout time 0sec.,no background infusion or dose-limit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Target-controlled infusion
Description: Anaesthesiologist´s managed target-controlled infusion of short-acting anesthetic propofol
Study: NCT01921790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin 7.5mg/Kg, intravenous drip D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1g/m2 intravenous drip D1,D8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2 intravenous drip D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Pegaspargase 2500U/m2 intramuscular injection (IM) D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20mg/d intravenous drip D1, po D2-3
Study: NCT02122653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight training
Description: Participants will perform 4 weeks of Weight training for lower extremities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic muscle stimulator
Description: Participants will perform 4 weeks of electrical stimulation for Quadriceps muscle belly.
Study: NCT02736968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auranofin
Description: Auranofin is a gold-containing chemical salt available as 3mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auranofin
Description: Auranofin is a gold-containing chemical salt available as 3mg capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00628914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram and eszopiclone
Description: escitalopram 10mg tabs QD and eszopiclone 3 mg tabs QD for 8 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram, eszopiclone, and placebo
Description: Escitalopram 10mg tabs QD for 8 weeks; Eszopiclone 3mg tabs QD for initial 4 weeks then placebo tabs QD for final 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10mg tabs QD and placebo tabs QD for 8 weeks
Study: NCT04318093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986259
Description: Specified dose on specified days
Study: NCT02899481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transabdominal and transperineal ultrasound
Description: Transabdominal ultrasound, for determining fetal head position, is performed with the pregnant women in supine position after bladder emptying, with the transducer placed transversely on the suprapubic region of the maternal abdomen. For the sonographic determination of the fetal descent we will perform a transperineal ultrasound achieved by placing the ultrasound transducer on the perineum in a mid sagittal position between the labia below the pubic symphysis.
Study: NCT04318093

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT02998021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Dumbbell
Description: Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks. The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively, first by increasing the frequency of the vibration (max. 40 Hz) then by the addition of more weight, based on weekly assessments and consultation with the senior investigators.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dumbbell
Description: Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks.~The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively by the addition of more weight, based on weekly assessments and consultation with the senior investigators.~To obtain as much data as possible on resistance training with vibration within study timeline, a modification was recently approved by the Institutional Review Board (IRB) to cease enrolling subjects into standard dumbbell training.
Study: NCT02973555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: autologous intrauterine infusion of PRP
Study: NCT02057003

Intervention type: DRUG
Intervention: DAA against HCV
Study: NCT01695733

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent influenza vaccine
Study: NCT05031676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: opioid free anesthesia
Description: Maintenance of anesthesia was done with halothane. The incision was allowed at 1.2 MAC of halothane. This halogen was administered according to the hemodynamic parameters and the habits of the anesthesia team. Before waking up, all the patients benefited from preventive analgesia with 1 g paracetamol combined with 20 mg nefopam by slow intravenous injection over approximately 15 minutes.
Study: NCT03150927

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Microbial Composite
Description: 125mg (or 250 mg) of BiOWiSH Probiotic Microbial Composite™ is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 125mg (or 250 mg) of Placebo is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
Study: NCT03100994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: injecting anesthetics to different local

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: injecting anesthetics to different local

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound guided nerve block

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound guided nerve block
Study: NCT01476488

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: tacrolimus
Study: NCT04723849

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Auxilie® Immuplus, Envicon Medical, Verona, Italy
Description: Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study. Height (cm) and weight (kg) were measured for each child at every visit. Endothelial function was assessed using two methodologies: a post occlusive release hyperemic test (PORH) and a heat provocation test (HPT).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Auxilie® Immuplus, Envicon Medical, Verona, Italy
Description: Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study. Height (cm) and weight (kg) were measured for each child at every visit. Endothelial function was assessed using two methodologies: a post occlusive release hyperemic test (PORH) and a heat provocation test (HPT).
Study: NCT02844491

Intervention type: OTHER
Intervention: additional biological samples
Description: blood and tissue samples

Intervention type: OTHER
Intervention: additional biological samples
Description: blood and tissue samples
Study: NCT00610064

Intervention type: RADIATION
Group type: OTHER
Intervention: Baseline neuroimaging
Description: Baseline neuroimaging using PET and MRI of the brain in patients before sacral neuromodulation

Intervention type: RADIATION
Group type: OTHER
Intervention: Neuroimaging during sacral neuromodulation
Description: Neuroimaging during sacral neuromodulation using PET
Study: NCT01283321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human fibrinogen concentrate
Description: 4 g IV once, within 30 minutes of ACT \< 155 seconds, post CPB, with evidence of significant microvascular bleeding

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: apheresis platelets
Description: A single apheresis platelet unit will be administered as an initial therapy within 30 minutes of ACT \<155 seconds post CPB with evidence of significant microvascular bleeding.
Study: NCT01928680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Capecitabine
Description: Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity
Study: NCT02751463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunscreening Sport Spray Rest (BAY987519)
Description: 50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.(Formulation Number - RB# Y51-002 )

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated skin
Description: One site is patched without treatment as control